{"id":169456,"date":"2023-08-11T08:22:21","date_gmt":"2023-08-11T13:22:21","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2023\/08\/maxcyte-signs-strategic-platform-license-with-prime-medicine-to-advance-next-generation-gene-editing-therapies-for-patients"},"modified":"2023-08-11T08:22:21","modified_gmt":"2023-08-11T13:22:21","slug":"maxcyte-signs-strategic-platform-license-with-prime-medicine-to-advance-next-generation-gene-editing-therapies-for-patients","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2023\/08\/maxcyte-signs-strategic-platform-license-with-prime-medicine-to-advance-next-generation-gene-editing-therapies-for-patients","title":{"rendered":"MaxCyte signs strategic platform license with prime medicine to advance next-generation gene editing therapies for patients"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/maxcyte-signs-strategic-platform-license-with-prime-medicine-to-advance-next-generation-gene-editing-therapies-for-patients.jpg\"><\/a><\/p>\n<p>MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced the signing of a strategic partnership with Prime Medicine, Inc., a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced the signing of a strategic partnership with Prime Medicine, Inc., a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies.<\/p>\n","protected":false},"author":511,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1902,11,412],"tags":[],"class_list":["post-169456","post","type-post","status-publish","format-standard","hentry","category-bioengineering","category-biotech-medical","category-genetics"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/169456","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/511"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=169456"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/169456\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=169456"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=169456"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=169456"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}